CC
Commodore Capital Portfolio holdings
AUM
$1.42B
This Quarter Return
+8.44%
1 Year Return
+73.3%
3 Year Return
+1,330.82%
5 Year Return
–
10 Year Return
–
AUM
$287M
AUM Growth
+$287M
(+14%)
Cap. Flow
+$29.6M
Cap. Flow
% of AUM
10.3%
Top 10 Holdings %
Top 10 Hldgs %
59.07%
Holding
34
New
3
Increased
15
Reduced
4
Closed
5
Top Buys
| 1 |
Celcuity
CELC
|
$20.9M |
| 2 |
Cytokinetics
CYTK
|
$13.9M |
| 3 |
Aclaris Therapeutics
ACRS
|
$11.3M |
| 4 |
MacroGenics
MGNX
|
$9.33M |
| 5 |
STSA
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
|
$4.69M |
Top Sells
| 1 |
FPRX
Five Prime Therapeutics, Inc.
FPRX
|
$13.6M |
| 2 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$8.55M |
| 3 |
Protagonist Therapeutics
PTGX
|
$6.24M |
| 4 |
Relmada Therapeutics
RLMD
|
$5.69M |
| 5 |
Syndax Pharmaceuticals
SNDX
|
$5.29M |
Sector Composition
| 1 | Healthcare | 99.08% |
| 2 | Financials | 0.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Astria Therapeutics
ATXS
$366M
| $3.41M | 1.19% |
+1,617,000
| New | +$3.41M |
|
27
Viridian Therapeutics
VRDN
$1.52B
| $3.41M | 1.19% |
186,405
+624
| +0.3% | +$11.4K |
|
28
ARS Pharmaceuticals
SPRY
$1.1B
| $3M | 1.05% |
97,143
| – | – |
|
|
BLSA
29
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
| $2.63M | 0.92% |
250,000
| – | – |
|
|
30
Relmada Therapeutics
RLMD
$48.1M
| – | – |
-161,565
| Closed | -$5.69M |
|
|
31
Syndax Pharmaceuticals
SNDX
$1.38B
| – | – |
-236,500
| Closed | -$5.29M |
|
|
SNCE
32
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| – | – |
-100,000
| Closed | -$1.01M |
|
|
TRIL
33
DELISTED
Trillium Therapeutics Inc.
TRIL
| – | – |
-795,868
| Closed | -$8.55M |
|
|
FPRX
34
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| – | – |
-361,344
| Closed | -$13.6M |
|